Price Watch · The Ledger

The compounded semaglutide price war: who's actually winning

For two years compounded GLP-1s undercut brand by 80%. Then brand prices collapsed to $149–$349. The gap has closed — and most patients haven't recalculated.

For two years the compounded GLP-1 pitch was simple: the same active ingredient as Wegovy, at 80% off. That pitch is dying — not because compounded prices went up, but because brand prices collapsed.

What the brand side did

	List price (was)	Direct-to-consumer (now)
Semaglutide tablets	~$1,349/mo	$149–$299/mo
Semaglutide injections	~$1,349/mo	$199–$349/mo
Tirzepatide injections	~$1,087/mo	$299–$449/mo

Direct-to-consumer pricing via manufacturer programs and the TrumpRx platform, launched February 2026. Pricing varies by product and dose and changes frequently — verify current pricing directly.

What the compounded side charges

Provider	Compounded semaglutide	Model
TrimRx	$199/mo flat	No dose surcharge
FormBlends	~$199/mo flat	No dose surcharge
Peter MD	$149–$165/mo equiv	Upfront multi-month bundle
MEDVi	$179 first mo → $299/mo	Step-up
Henry Meds	$297/mo (or ~$197 on 12-mo prepay)	Step-up + $100/dose tier
Willow	$299/mo	Flat

The uncomfortable conclusion

Those two tables now overlap. A flat $199/mo compounded semaglutide and a $199/mo brand semaglutide injection are the same price — except one is FDA-approved as a finished product and one isn't. The compounded market's core value proposition has been substantially eroded, and most patients haven't recalculated.

Who's actually winning

Flat-rate compounders (TrimRx, FormBlends) — still competitive on price, and they can offer doses and formats the brand doesn't make. They survive.
Step-up pricers (MEDVi, Henry Meds at month-to-month) — hardest hit. A $299/mo refill no longer undercuts brand direct pricing at all.
Brand manufacturers — clearly winning. They cut price, kept the FDA approval, and got the FDA to squeeze the compounders simultaneously.
Medicare enrollees — the biggest winners. $50/mo via the GLP-1 Bridge.

The regulatory pincer

Price competition isn't the only pressure. The semaglutide shortage was declared resolved in February 2025 and tirzepatide in December 2024, which narrowed the legal authority for large-scale compounding. The FDA has issued 80+ warning letters since September 2025 and announced in February 2026 that it intends to restrict GLP-1 active ingredients used in mass-marketed non-approved compounded products. Full enforcement timeline →

What you should actually do

Price the brand direct programs for your specific dose. Then price a flat-rate compounded provider. If compounded still wins for your dose or you need a format the brand doesn't make, take it — from a provider that names its pharmacy. If it doesn't win, stop paying a premium for a non-approved product. Full comparison →

FAQ

Is compounded semaglutide still cheaper than brand?

Often not. Manufacturer direct-to-consumer programs now list brand semaglutide injections at roughly $199–$349/mo, which overlaps directly with compounded telehealth pricing ($149–$299/mo). Flat-rate compounders remain competitive; step-up pricers largely don't.

Why did brand GLP-1 prices drop so much?

Manufacturer direct-to-consumer programs and the TrumpRx platform (launched February 2026) cut cash prices dramatically from the ~$1,349 list. This coincided with FDA pressure on compounders after the semaglutide and tirzepatide shortages were declared resolved.

Which compounded provider offers the best value now?

Flat-rate providers hold up best. TrimRx at $199/mo flat and FormBlends at roughly $199/mo flat don't add dose-escalation surcharges, so their six-month totals stay predictable and competitive.

Medical disclaimer: Veritide is an independent consumer-research publication, not a healthcare provider or pharmacy. This page is informational and is not medical advice. Compounded medications are not FDA-approved as finished products. Always consult a licensed clinician before starting any peptide or GLP-1 therapy.